# Milton Packer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8056350/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 577 papers | 95,822 citations | 553 126 h-index | 269 297 g-index |
| 602 all docs | 602 docs citations | 602 times ranked | 41679 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 1992, 327, 669-677. | 13.9 | 5,567 |
| 2 | Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004. | 13.9 | 5,052 |
| 3 | Cardiac Resynchronization in Chronic Heart Failure. New England Journal of Medicine, 2002, 346, 1845-1853. | 13.9 | 4,365 |
| 4 | The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. New England Journal of Medicine, 1996, 334, 1349-1355. | 13.9 | 4,294 |
| 5 | Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy. Cell, 2005, 122, 927-939. | 13.5 | 3,204 |
| 6 | Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine, 2001, 344, 1651-1658. | 13.9 | 2,909 |
| 7 | Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424. | 13.9 | 2,821 |
| 8 | Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure. New England Journal of Medicine, 1990, 323, 236-241. | 13.9 | 2,370 |
| 9 | Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461. | 13.9 | 2,143 |
| 10 | Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. New England Journal of Medicine, 1991, 325, 1468-1475. | 13.9 | 2,137 |
| 11 | The Seattle Heart Failure Model. Circulation, 2006, 113, 1424-1433. | 1.6 | 1,744 |
| 12 | Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620. | 13.9 | 1,485 |
| 13 | Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Î±, in Patients With Moderate-to-Severe Heart Failure. Circulation, 2003, 107, 3133-3140. | 1.6 | 1,401 |
| 14 | ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 21 | 1.6 | 1,204 |
| 15 | Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. New England Journal of Medicine, 1996, 335, 1107-1114. | 13.9 | 1,141 |
| 16 | Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure. Circulation, 2002, 106, 2194-2199. | 1.6 | 1,132 |
| 17 | Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. Circulation, 2004, 109, 1594-1602. | 1.6 | 1,062 |
| 18 | Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation, 1999, 100, 2312-2318. | 1.6 | 1,031 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395. | 6.3 | 990 |
| 20 | Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature, 2012, 481, 511-515. | 13.7 | 975 |
| 21 | The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. Journal of the American College of Cardiology, 1992, 20, 248-254. | 1.2 | 956 |
| 22 | Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors. New England Journal of Medicine, 1993, 329, 1-7. | 13.9 | 853 |
| 23 | Sex Differences in the Management of Coronary Artery Disease. New England Journal of Medicine, 1991, 325, 226-230. | 13.9 | 847 |
| 24 | Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure. JAMA - Journal of the American Medical Association, 2007, 297, 1883. | 3.8 | 834 |
| 25 | SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829. | 6.3 | 816 |
| 26 | Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 447-456. | 1.2 | 591 |
| 27 | Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. Circulation, 2002, 106, 920-926. | 1.6 | 582 |
| 28 | Neurohormonal interactions and adaptations in congestive heart failure.. Circulation, 1988, 77, 721-730. | 1.6 | 564 |
| 29 | Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.. Circulation, 1986, 73, 257-267. | 1.6 | 556 |
| 30 | Clinical Effects of Î²-Adrenergic Blockade in Chronic Heart Failure. Circulation, 1998, 98, 1184-1191. | 1.6 | 553 |
| 31 | Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61. | 1.6 | 552 |
| 32 | Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. Circulation, 1996, 94, 2793-2799. | 1.6 | 530 |
| 33 | Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure. Circulation, 1996, 94, 2800-2806. | 1.6 | 526 |
| 34 | Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. Journal of Clinical Oncology, 2014, 32, 2380-2385. | 0.8 | 501 |
| 35 | Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension, 2004, 17, 103-111. | 1.0 | 492 |
| 36 | Proportionate and Disproportionate Functional Mitral Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 353-362. | 2.3 | 472 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35. | 1.0 | 426 |
| 38 | Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.. Circulation, 1982, 65, 660-668. | 1.6 | 420 |
| 39 | Prostaglandins in Severe Congestive Heart Failure. New England Journal of Medicine, 1984, 310, 347-352. | 13.9 | 417 |
| 40 | Guidelines for the Evaluation and Management of Heart Failure. Circulation, 1995, 92, 2764-2784. | 1.6 | 407 |
| 41 | Predictors of total mortality and sudden death in mild to moderate heart failure. Journal of the American College of Cardiology, 1989, 14, 564-570. | 1.2 | 388 |
| 42 | Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure. New England Journal of Medicine, 1987, 317, 799-804. | 13.9 | 378 |
| 43 | Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128. | 6.3 | 376 |
| 44 | Sudden unexpected death in patients with congestive heart failure: a second frontier.. Circulation, 1985, 72, 681-685. | 1.6 | 371 |
| 45 | Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. Journal of Cardiac Failure, 2001, 7, 176-182. | 0.7 | 366 |
| 46 | Pathophysiology of chronic heart failure. Lancet, The, 1992, 340, 88-92. | 6.3 | 362 |
| 47 | Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2013, 15, 1062-1073. | 2.9 | 358 |
| 48 | Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. Journal of the American College of Cardiology, 2018, 71, 2360-2372. | 1.2 | 356 |
| 49 | Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51. | 13.9 | 355 |
| 50 | Reversal of Chronic Ventricular Dilation in Patients With End-Stage Cardiomyopathy by Prolonged Mechanical Unloading. Circulation, 1995, 91, 2717-2720. | 1.6 | 348 |
| 51 | Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. Journal of the American College of Cardiology, 1989, 13, 1534-1539. | 1.2 | 342 |
| 52 | Effect of Levosimendan on the Short-TermÂClinical Course of Patients With AcutelyÂDecompensated Heart Failure. JACC: Heart Failure, 2013, 1, 103-111. | 1.9 | 337 |
| 53 | The REMATCH trial: rationale, design, and end points. Annals of Thoracic Surgery, 1999, 67, 723-730. | 0.7 | 336 |
| 54 | Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 2015, 36, 1990-1997. | 1.0 | 335 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361. | 1.6 | 335 |
| 56 | Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal, 2002, 144, 31-38. | 1.2 | 322 |
| 57 | Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure. Circulation, 1995, 92, 1499-1506. | 1.6 | 316 |
| 58 | Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.. Circulation, 1994, 90, 1731-1738. | 1.6 | 311 |
| 59 | Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure: Basis of a new physiologic approach to control of arrhythmia. American Journal of Medicine, 1986, 80, 23-29. | 0.6 | 302 |
| 60 | Comparison of Captopril and Enalapril in Patients with Severe Chronic Heart Failure. New England Journal of Medicine, 1986, 315, 847-853. | 13.9 | 302 |
| 61 | Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death. Circulation, 2000, 102, 611-616. | 1.6 | 298 |
| 62 | Prognostic Impact of Plasma N-Terminal Proâ€“Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure. Circulation, 2004, 110, 1780-1786. | 1.6 | 282 |
| 63 | Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology, 2017, 2, 1025. | 3.0 | 280 |
| 64 | Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine, 2001, 344, 1358-1365. | 13.9 | 277 |
| 65 | Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. Journal of the American College of Cardiology, 1994, 24, 583-591. | 1.2 | 274 |
| 66 | Development of autophagy inducers in clinical medicine. Journal of Clinical Investigation, 2015, 125, 14-24. | 3.9 | 274 |
| 67 | Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498. | 1.9 | 272 |
| 68 | Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Journal of the American College of Cardiology, 2016, 68, 2425-2436. | 1.2 | 271 |
| 69 | Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure. Circulation, 1996, 94, 3184-3189. | 1.6 | 265 |
| 70 | Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2003, 289, 712. | 3.8 | 261 |
| 71 | Risk Related to Preâ€“Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, . | 1.6 | 260 |
| 72 | Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 333-340. | 5.5 | 258 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. New England Journal of Medicine, 2017, 376, 1956-1964. | 13.9 | 257 |
| 74 | Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. Journal of Cardiac Failure, 2005, 11, 12-20. | 0.7 | 250 |
| 75 | Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review. Journal of General Internal Medicine, 2012, 27, 861-867. | 1.3 | 245 |
| 76 | Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351. | 1.6 | 244 |
| 77 | Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482. | 1.9 | 238 |
| 78 | Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.. Circulation, 1979, 59, 531-539. | 1.6 | 237 |
| 79 | Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.. Circulation, 1984, 70, 1038-1047. | 1.6 | 237 |
| 80 | N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.. Circulation, 1994, 89, 1934-1942. | 1.6 | 232 |
| 81 | Heart Failure With a Normal Ejection Fraction. Circulation, 2003, 107, 656-658. | 1.6 | 226 |
| 82 | Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336. | 1.6 | 222 |
| 83 | Deleterious Effects of Hydralazine in Patients with Pulmonary Hypertension. New England Journal of Medicine, 1982, 306, 1326-1331. | 13.9 | 221 |
| 84 | Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349. | 1.6 | 217 |
| 85 | Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.. Circulation, 1985, 71, 963-971. | 1.6 | 209 |
| 86 | Evaluation of the effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287. | 2.9 | 205 |
| 87 | Ambulatory Ventricular Arrhythmias in Patients With Heart Failure Do Not Specifically Predict an Increased Risk of Sudden Death. Circulation, 2000, 101, 40-46. | 1.6 | 203 |
| 88 | Heart Rate and Rhythm and the BenefitÂofÂBeta-Blockers in PatientsÂWithÂHeart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896. | 1.2 | 198 |
| 89 | Safety and efficacy of carvedilol in severe heart failure. Journal of Cardiac Failure, 1997, 3, 173-179. | 0.7 | 197 |
| 90 | Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294. | 1.6 | 195 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1096-1103. | 2.9 | 194 |
| 92 | Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure. Annals of Internal Medicine, 1987, 106, 346. | 2.0 | 188 |
| 93 | Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584. | 1.0 | 187 |
| 94 | Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. Circulation, 2004, 110, 3667-3673. | 1.6 | 185 |
| 95 | Left Heart Failure With a Normal Ejection Fraction: Identification of Different Pathophysiologic Mechanisms. Journal of Cardiac Failure, 2005, 11, 177-187. | 0.7 | 184 |
| 96 | Sexâ€specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 535-542. | 2.9 | 184 |
| 97 | Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 405-413. | 3.1 | 184 |
| 98 | Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. Journal of the American College of Cardiology, 1995, 25, 289-294. | 1.2 | 178 |
| 99 | Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2006, 47, 2245-2252. | 1.2 | 175 |
| 100 | Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2016, 18, 1228-1234. | 2.9 | 173 |
| 101 | Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in PatientsÂWith HFrEF. Journal of the American College of Cardiology, 2019, 73, 795-806. | 1.2 | 173 |
| 102 | Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation, 2017, 136, 1548-1559. | 1.6 | 172 |
| 103 | Cardiovascular Drug Development. Journal of the American College of Cardiology, 2015, 65, 1567-1582. | 1.2 | 168 |
| 104 | Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40. | 1.2 | 168 |
| 105 | Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation, 2021, 143, 310-321. | 1.6 | 168 |
| 106 | Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. American Heart Journal, 2001, 141, 899-907. | 1.2 | 165 |
| 107 | Leptin-Aldosterone-Neprilysin Axis. Circulation, 2018, 137, 1614-1631. | 1.6 | 163 |
| 108 | ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Journal of Heart and Lung Transplantation, 2002, 21, 189-203. | 0.3 | 162 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143. | 1.0 | 160 |
| 110 | Evaluation of the effect of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278. | 2.9 | 155 |
| 111 | Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial Infarction. American Journal of Cardiology, 2006, 98, 39-45. | 0.7 | 153 |
| 112 | Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 510-517. | 2.9 | 153 |
| 113 | Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure, 2017, 10, . | 1.6 | 150 |
| 114 | Activation of neurohumoral systems in postinfarction left ventricular dysfunction. Journal of the American College of Cardiology, 1993, 22, 390-398. | 1.2 | 149 |
| 115 | How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?. Circulation, 2021, 143, 875-877. | 1.6 | 149 |
| 116 | Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€HF</scp>). European Journal of Heart Failure, 2014, 16, 817-825. | 2.9 | 148 |
| 117 | SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. Diabetes Care, 2020, 43, 508-511. | 4.3 | 147 |
| 118 | Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424. | 1.0 | 144 |
| 119 | Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2017, 2, 79. | 3.0 | 143 |
| 120 | Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262. | 1.6 | 142 |
| 121 | Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. European Heart Journal, 2000, 21, 1967-1978. | 1.0 | 141 |
| 122 | B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. Journal of the American College of Cardiology, 2019, 73, 1264-1272. | 1.2 | 139 |
| 123 | Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.. Circulation, 1985, 71, 761-766. | 1.6 | 137 |
| 124 | Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism. Journal of the American College of Cardiology, 1983, 2, 841-852. | 1.2 | 133 |
| 125 | Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.. Circulation, 1983, 68, 803-812. | 1.6 | 133 |
| 126 | Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. Journal of the American College of Cardiology, 2004, 43, 1423-1429. | 1.2 | 132 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Analytical and Clinical Evaluation of the Bayer ADVIA Centaur Automated B-Type Natriuretic Peptide Assay in Patients with Heart Failure: A Multisite Study. Clinical Chemistry, 2004, 50, 867-873. | 1.5 | 131 |
| 128 | Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002744. | 1.6 | 130 |
| 129 | Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2019, 21, 337-341. | 2.9 | 129 |
| 130 | Combined Beta-Adrenergic and Calcium-Entry Blockade in Angina Pectoris. New England Journal of Medicine, 1989, 320, 709-718. | 13.9 | 128 |
| 131 | Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Journal of the American College of Cardiology, 1993, 22, 65-72. | 1.2 | 128 |
| 132 | Rebound Hemodynamic Events after the Abrupt Withdrawal of Nitroprusside in Patients with Severe Chronic Heart Failure. New England Journal of Medicine, 1979, 301, 1193-1197. | 13.9 | 126 |
| 133 | Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 547-554. | 5.5 | 124 |
| 134 | Vasodilator Therapy for Primary Pulmonary Hypertension. Annals of Internal Medicine, 1985, 103, 258. | 2.0 | 122 |
| 135 | Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. Journal of the American College of Cardiology, 2007, 49, 1450-1458. | 1.2 | 121 |
| 136 | Correction of Dilutional Hyponatremia in Severe Chronic Heart Failure by Converting-Enzyme Inhibition. Annals of Internal Medicine, 1984, 100, 782. | 2.0 | 118 |
| 137 | Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope. Journal of the American College of Cardiology, 1988, 12, 1299-1317. | 1.2 | 118 |
| 138 | Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy.. Circulation, 1990, 82, 2254-2257. | 1.6 | 118 |
| 139 | Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071. | 1.2 | 118 |
| 140 | Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. Journal of the American College of Cardiology, 1984, 3, 1035-1043. | 1.2 | 117 |
| 141 | Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962. | 1.6 | 117 |
| 142 | Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics. American Journal of Kidney Diseases, 2021, 77, 280-286. | 2.1 | 115 |
| 143 | Is Tumor Necrosis Factor an Important Neurohormonal Mechanism in Chronic Heart Failure?. Circulation, 1995, 92, 1379-1382. | 1.6 | 115 |
| 144 | Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 2016, 37, 3167-3174. | 1.0 | 114 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500. | 1.2 | 114 |
| 146 | Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212. | 1.0 | 114 |
| 147 | Influenza Vaccination in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158. | 1.9 | 112 |
| 148 | Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. Journal of the American College of Cardiology, 1990, 16, 827-831. | 1.2 | 110 |
| 149 | How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. American Journal of Cardiology, 1993, 71, C3-C11. | 0.7 | 110 |
| 150 | Obesity-Related Heart Failure With a Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 633-639. | 1.9 | 108 |
| 151 | Should B-Type Natriuretic Peptide Be Measured Routinely to Guide the Diagnosis and Management of Chronic Heart Failure?. Circulation, 2003, 108, 2950-2953. | 1.6 | 107 |
| 152 | Hemodynamic Characterization of Tolerance to Long-Term Hydralazine Therapy in Severe Chronic Heart Failure. New England Journal of Medicine, 1982, 306, 57-62. | 13.9 | 106 |
| 153 | Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193. | 1.6 | 106 |
| 154 | Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1397-1407. | 1.2 | 105 |
| 155 | Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.. Circulation, 1981, 64, 506-514. | 1.6 | 103 |
| 156 | Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373. | 1.0 | 103 |
| 157 | Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors. Circulation: Heart Failure, 2020, 13, e007197. | 1.6 | 103 |
| 158 | Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system.. Circulation, 1986, 74, 766-774. | 1.6 | 101 |
| 159 | Influence of Sacubitril/Valsartan (LCZ696)ÂonÂ30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology, 2016, 68, 241-248. | 1.2 | 101 |
| 160 | Dose requirements of hydralazine in patients with severe chronic congestive heart failure. American Journal of Cardiology, 1980, 45, 655-660. | 0.7 | 99 |
| 161 | Î²-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Progress in Cardiovascular Diseases, 1998, 41, 39-52. | 1.6 | 99 |
| 162 | Importance of Left Ventricular Chamber Size in Determining the Response to Hydralazine in Severe Chronic Heart Failure. New England Journal of Medicine, 1980, 303, 250-255. | 13.9 | 98 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. Journal of the American College of Cardiology, 1987, 9, 433-438. | 1.2 | 97 |
| 164 | Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).. Circulation, 1993, 88, 492-501. | 1.6 | 97 |
| 165 | The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. Journal of Cardiac Failure, 2004, 10, 101-112. | 0.7 | 97 |
| 166 | Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. Journal of the American College of Cardiology, 1984, 4, 890-901. | 1.2 | 96 |
| 167 | Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541. | 1.6 | 96 |
| 168 | Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 671-680. | 1.0 | 96 |
| 169 | Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated With Estrogen Receptor-Negative Subtypes and Poor Prognosis. EBioMedicine, 2015, 2, 255-263. | 2.7 | 95 |
| 170 | Effect of age and sex on efficacy and tolerability of Î² blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855. | 3.0 | 95 |
| 171 | Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137. | 2.9 | 95 |
| 172 | Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465. | 1.9 | 94 |
| 173 | Empagliflozin in Patients With HeartÂFailure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology, 2021, 77, 1381-1392. | 1.2 | 94 |
| 174 | Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392. | 2.9 | 93 |
| 175 | Characterization of the <scp>inflammatoryâ€metabolic</scp> phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. European Journal of Heart Failure, 2020, 22, 1551-1567. | 2.9 | 93 |
| 176 | Primary pulmonary hypertension associated with human immunodeficiency viral infection. American Journal of Medicine, 1990, 89, 96-99. | 0.6 | 92 |
| 177 | Estimating the Long-Term Treatment Benefits of Sacubitrilâ€“Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290. | 13.9 | 92 |
| 178 | Changes in plasma endothelin-1 levels reflect clinical response to Î²-blockade in chronic heart failure. American Heart Journal, 1996, 131, 337-341. | 1.2 | 91 |
| 179 | Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 317-326. | 1.9 | 91 |
| 180 | Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. Annals of Thoracic Surgery, 1994, 58, 1515-1520. | 0.7 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Prior HeartÂFailure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. Journal of the American College of Cardiology, 2020, 75, 245-254. | 1.2 | 88 |
| 182 | Rapid evidenceâ€based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 882-894. | 2.9 | 88 |
| 183 | Indications for left ventricular aneurysmectomy.. Circulation, 1983, 67, 717-722. | 1.6 | 85 |
| 184 | Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?. Journal of the American College of Cardiology, 1996, 28, 1323-1327. | 1.2 | 85 |
| 185 | NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. European Journal of Heart Failure, 2004, 6, 343-350. | 2.9 | 85 |
| 186 | The prevalence and importance of frailty in heart failure with reduced ejection fractionÂâ€“Âan analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2020, 22, 2123-2133. | 2.9 | 85 |
| 187 | Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology, 1987, 10, 837-844. | 1.2 | 84 |
| 188 | Efficacy of Sacubitril/Valsartan Relative toÂa Prior Decompensation. JACC: Heart Failure, 2016, 4, 816-822. | 1.9 | 84 |
| 189 | Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498. | 3.0 | 84 |
| 190 | Role of endothelin in the exercise intolerance of chronic heart failure. American Journal of Cardiology, 1995, 75, 1282-1283. | 0.7 | 83 |
| 191 | Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQq1 1 0.784314 rgBT /Over Therapy. Circulation: Heart Failure, 2016, 9, . | 1.6 | 83 |
| 192 | Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. Circulation, 2020, 141, 4-6. | 1.6 | 81 |
| 193 | Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245. | 1.6 | 81 |
| 194 | Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors. Journal of the American Society of Nephrology: JASN, 2020, 31, 907-919. | 3.0 | 81 |
| 195 | Treatment of chronic heart failure. Lancet, The, 1992, 340, 92-95. | 6.3 | 80 |
| 196 | Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959. | 1.6 | 80 |
| 197 | A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439. | 1.0 | 80 |
| 198 | New Evidence Supporting a Novel Conceptual Framework for Distinguishing Proportionate and Disproportionate Functional Mitral Regurgitation. JAMA Cardiology, 2020, 5, 469. | 3.0 | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3442-3451. | 1.0 | 78 |
| 200 | What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?. European Heart Journal, 2020, 41, 1757-1763. | 1.0 | 78 |
| 201 | Empagliflozin and Major Renal Outcomes in Heart Failure. New England Journal of Medicine, 2021, 385, 1531-1533. | 13.9 | 78 |
| 202 | Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2019, 7, 862-874. | 1.9 | 77 |
| 203 | Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure. Archives of Internal Medicine, 2001, 161, 165. | 4.3 | 76 |
| 204 | Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care, 2018, 41, 11-13. | 4.3 | 76 |
| 205 | Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodiumâ€“glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2020, 22, 618-628. | 2.9 | 76 |
| 206 | Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC: Heart Failure, 2013, 1, 308-314. | 1.9 | 75 |
| 207 | Do sodiumâ€glucose coâ€transporterâ€2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes, Obesity and Metabolism, 2018, 20, 1361-1366. | 2.2 | 75 |
| 208 | Clinical relevance of verapamil plasma levels in stable angina pectoris. American Journal of Cardiology, 1982, 50, 1180-1184. | 0.7 | 74 |
| 209 | Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. American Journal of Cardiology, 1997, 80, 1101-1104. | 0.7 | 74 |
| 210 | Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489. | 2.9 | 74 |
| 211 | Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379. | 1.6 | 74 |
| 212 | Nitroglycerin therapy in the management of pulmonary hypertensive disorders. American Journal of Medicine, 1984, 76, 67-75. | 0.6 | 73 |
| 213 | The Search for the Ideal Positive Inotropic Agent. New England Journal of Medicine, 1993, 329, 201-202. | 13.9 | 72 |
| 214 | Effect of betaâ€adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 549-556. | 2.9 | 71 |
| 215 | Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure. American Journal of Cardiology, 1986, 57, 260-267. | 0.7 | 70 |
| 216 | Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failure. Progress in Cardiovascular Diseases, 1982, 24, 275-292. | 1.6 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. Journal of the American College of Cardiology, 1987, 10, 1303-1311. | 1.2 | 69 |
| 218 | Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The Promise Study. Journal of the American College of Cardiology, 1993, 21, 634-640. | 1.2 | 69 |
| 219 | Sudden death in heart failure: vascular or electrical?. European Journal of Heart Failure, 1999, 1, 41-45. | 2.9 | 69 |
| 220 | Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation, 1990, 81, III78-86. | 1.6 | 68 |
| 221 | Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <scp>LCZ696</scp>, in patients with heart failure with preserved ejection fraction: an analysis of the <scp>PARAMOUNT</scp> trial. European Journal of Heart Failure, 2014, 16, 671-677. | 2.9 | 67 |
| 222 | Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovascular Diabetology, 2020, 19, 62. | 2.7 | 67 |
| 223 | Effects of sudden change in cycle length on human atrial, atrioventricular nodal and ventricular refractory periods.. Circulation, 1981, 64, 245-248. | 1.6 | 66 |
| 224 | The Erythrocyte Sedimentation Rate in Congestive Heart Failure. New England Journal of Medicine, 1991, 324, 353-358. | 13.9 | 66 |
| 225 | Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840. | 1.9 | 65 |
| 226 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117. | 1.0 | 65 |
| 227 | Worsening Heart Failure During theÂUseÂof DPP-4 Inhibitors. JACC: Heart Failure, 2018, 6, 445-451. | 1.9 | 63 |
| 228 | Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346. | 1.9 | 63 |
| 229 | Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.. Circulation, 1990, 81, 860-864. | 1.6 | 62 |
| 230 | Do Î²-blockers prolong survival in heart failure only by inhibiting the Î²1-receptor? A perspective on the results of the COMET trial. Journal of Cardiac Failure, 2003, 9, 429-443. | 0.7 | 62 |
| 231 | Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2018, 20, 760-768. | 2.9 | 62 |
| 232 | Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. Journal of the American College of Cardiology, 2001, 37, 1692-1699. | 1.2 | 61 |
| 233 | Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal, 2014, 35, 42-47. | 1.0 | 61 |
| 234 | Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance. Circulation, 2020, 141, 2095-2105. | 1.6 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432. | 3.0 | 59 |
| 236 | Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. American Heart Journal, 1987, 113, 137-143. | 1.2 | 58 |
| 237 | Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?. Circulation Research, 2018, 122, 928-932. | 2.0 | 58 |
| 238 | Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 11, e004446. | 1.6 | 58 |
| 239 | Quantification of valve regurgitation by radionuclide angiography before and after valve replacement surgery. American Journal of Cardiology, 1981, 47, 287-291. | 0.7 | 57 |
| 240 | End of the Oldest Controversy in Medicine â€" Are We Ready to Conclude the Debate on Digitalis?. New England Journal of Medicine, 1997, 336, 575-576. | 13.9 | 57 |
| 241 | Interplay of adenosine monophosphateâ€activated protein kinase/sirtuinâ€1 activation and sodium influx inhibition mediates the renal benefits of sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes: A novel conceptual framework. Diabetes, Obesity and Metabolism, 2020, 22, 734-742. | 2.2 | 57 |
| 242 | Characterization, Pathogenesis, and Clinical Implications of Inflammationâ€Related Atrial Myopathy as an Important Cause of Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e015343. | 1.6 | 57 |
| 243 | Circadian rhythm and sudden death in heart failure. Journal of the American College of Cardiology, 2000, 36, 541-546. | 1.2 | 56 |
| 244 | Growth differentiation factorâ€15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2018, 20, 1701-1709. | 2.9 | 56 |
| 245 | Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and HeartÂFailure Cause. JACC: Heart Failure, 2020, 8, 844-855. | 1.9 | 56 |
| 246 | Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. Circulation: Heart Failure, 2018, 11, e004745. | 1.6 | 55 |
| 247 | Contrasting Effects of Pharmacological, Procedural, and Surgical Interventions on Proportionate and Disproportionate Functional Mitral Regurgitation in Chronic Heart Failure. Circulation, 2019, 140, 779-789. | 1.6 | 55 |
| 248 | Prognostic Importance of NT-proBNP andÂEffect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332. | 1.2 | 55 |
| 249 | Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. European Heart Journal, 1995, 16, 4-6. | 1.0 | 54 |
| 250 | The prognostic value of troponin T and Nâ€terminal pro Bâ€type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49. | 2.9 | 54 |
| 251 | Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, . | 1.6 | 53 |
| 252 | Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, . | 1.6 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders. JACC Basic To Translational Science, 2020, 5, 961-968. | 1.9 | 53 |
| 254 | Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors. Journal of Cardiac Failure, 2020, 26, 977-984. | 0.7 | 53 |
| 255 | Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381. | 1.9 | 53 |
| 256 | Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?. Circulation, 1989, 79, 198-204. | 1.6 | 52 |
| 257 | Cobalt Cardiomyopathy. Circulation: Heart Failure, 2016, 9, . | 1.6 | 52 |
| 258 | Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circulation: Heart Failure, 2016, 9, . | 1.6 | 52 |
| 259 | Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Circulation, 2019, 140, 443-445. | 1.6 | 52 |
| 260 | Empagliflozin Improves Cardiovascular and Renal Outcomes in HeartÂFailure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348. | 1.2 | 52 |
| 261 | Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. American Journal of Cardiology, 1987, 60, 179-184. | 0.7 | 51 |
| 262 | Clinical and regulatory implications of the cardiac arrhythmia suppression trial. American Journal of Cardiology, 1990, 65, 103-105. | 0.7 | 51 |
| 263 | Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovascular Research, 2021, 117, 74-84. | 1.8 | 51 |
| 264 | Differential Pathophysiological Mechanisms in HeartÂFailure With a Reduced or Preserved Ejection FractionÂin Diabetes. JACC: Heart Failure, 2021, 9, 535-549. | 1.9 | 50 |
| 265 | Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris. American Journal of Cardiology, 1982, 50, 903-912. | 0.7 | 48 |
| 266 | Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. American Heart Journal, 2000, 139, 503-510. | 1.2 | 48 |
| 267 | Redefining Heart Failure With a Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1761. | 3.8 | 48 |
| 268 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. Journal of the American College of Cardiology, 1986, 7, 671-680. | 1.2 | 46 |
| 269 | Patients With Mild Heart Failure Worsen During Withdrawal From Digoxin Therapy. Journal of the American College of Cardiology, 1997, 30, 42-48. | 1.2 | 46 |
| 270 | Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. European Heart Journal, 2001, 22, 1601-1612. | 1.0 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. European Journal of Heart Failure, 2020, 22, 214-227. | 2.9 | 46 |
| 272 | Relation between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation. Journal of the American College of Cardiology, 1984, 3, 924-929. | 1.2 | 45 |
| 273 | Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. American Journal of Cardiology, 1986, 57, 347-348. | 0.7 | 45 |
| 274 | The impossible task of developing a new treatment for heart failure. Journal of Cardiac Failure, 2002, 8, 193-196. | 0.7 | 45 |
| 275 | Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. American Heart Journal, 2005, 150, 257-262. | 1.2 | 45 |
| 276 | Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovascular Diabetology, 2019, 18, 129. | 2.7 | 45 |
| 277 | Physical Training Alters the Pathogenesis of Pacing-Induced Heart Failure Through Endothelium-Mediated Mechanisms in Awake Dogs. Circulation, 1997, 96, 2683-2692. | 1.6 | 45 |
| 278 | Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet, The, 2017, 389, 1831-1840. | 6.3 | 44 |
| 279 | Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials ofÂHeart Failure. JACC: Heart Failure, 2018, 6, 564-569. | 1.9 | 43 |
| 280 | Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation. European Heart Journal, 2019, 40, 1873-1879. | 1.0 | 43 |
| 281 | Coronary Endothelial Dysfunction Precedes Heart Failure and Reduction of Coronary Reserve in Awake Dogs. Journal of Molecular and Cellular Cardiology, 1997, 29, 217-227. | 0.9 | 42 |
| 282 | Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan. American Heart Journal, 2000, 139, 587-595. | 1.2 | 42 |
| 283 | New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. Journal of Internal Medicine, 1996, 239, 327-333. | 2.7 | 41 |
| 284 | Guidelineâ€directed medical therapy for heart failure does not exist: a nonâ€judgmental framework for describing the level of adherence to evidenceâ€based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1759-1767. | 2.9 | 41 |
| 285 | Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2573-2587. | 1.0 | 41 |
| 286 | Long-term effectiveness of verapamil in stable and unstable angina pectoris. American Journal of Cardiology, 1982, 50, 1185-1190. | 0.7 | 40 |
| 287 | Congestive heart failure: Current controversies and future prospects. American Journal of Cardiology, 1990, 66, 429-430. | 0.7 | 40 |
| 288 | IGFBP7 (Insulin-Like Growth Factorâ€“Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circulation: Heart Failure, 2018, 11, e005133. | 1.6 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure. European Heart Journal, 2020, 41, 3856-3861. | 1.0 | 40 |
| 290 | Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation, 1992, 85, I50-6. | 1.6 | 40 |
| 291 | Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1986, 57, 1323-1327. | 0.7 | 39 |
| 292 | Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904. | 1.2 | 39 |
| 293 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446. | 1.0 | 39 |
| 294 | Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. Journal of Cardiac Failure, 1998, 4, 3-8. | 0.7 | 38 |
| 295 | Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226. | 3.0 | 38 |
| 296 | Diseaseâ€“treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovascular Diabetology, 2019, 18, 121. | 2.7 | 38 |
| 297 | Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587. | 2.9 | 38 |
| 298 | A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362. | 1.0 | 38 |
| 299 | Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451. | 1.0 | 38 |
| 300 | Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. American Journal of Cardiology, 1981, 48, 939-946. | 0.7 | 37 |
| 301 | The placebo effect in heart failure. American Heart Journal, 1990, 120, 1579-1582. | 1.2 | 37 |
| 302 | Can Brain Natriuretic Peptide Be Used to Guide the Management of Patients With Heart Failure and a Preserved Ejection Fraction?. Circulation: Heart Failure, 2011, 4, 538-540. | 1.6 | 37 |
| 303 | Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 986-1003. | 0.7 | 37 |
| 304 | Cumulative Hemodynamic Response to Short-Term Treatment with Flosequinan (BTS 49465), a New Direct-Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1988, 12, 6-11. | 0.8 | 36 |
| 305 | Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. American Journal of Cardiology, 1991, 67, 63-66. | 0.7 | 36 |
| 306 | Effects of Beta-Adrenergic Blockade on Survival of Patients With Chronic Heart Failure. American Journal of Cardiology, 1997, 80, 46L-54L. | 0.7 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1567-1569. | 2.9 | 36 |
| 308 | Digoxin Discontinuation and Outcomes inÂPatients With HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2019, 74, 617-627. | 1.2 | 36 |
| 309 | Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With HeartÂFailure and Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137. | 1.2 | 36 |
| 310 | Efficacy of captopril in low-renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. American Journal of Cardiology, 1984, 54, 771-777. | 0.7 | 35 |
| 311 | $beta;-Blockade in Heart FailureBasic Concepts and Clinical Results. American Journal of Hypertension, 1998, 11, 23S-37S. | 1.0 | 35 |
| 312 | Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Circulation, 2016, 134, 1785-1787. | 1.6 | 35 |
| 313 | Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522. | 2.9 | 35 |
| 314 | Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Medicine, 2020, 133, 170-177. | 0.6 | 35 |
| 315 | Incidence and Outcomes of Pneumonia in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1961-1973. | 1.2 | 35 |
| 316 | Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure. Circulation, 2016, 134, 1664-1678. | 1.6 | 34 |
| 317 | Derangements in adrenergicâ€“adipokine signalling establish a neurohormonal basis for obesityâ€related heart failure with a preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 873-878. | 2.9 | 34 |
| 318 | Serum potassium in the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2020, 22, 2056-2064. | 2.9 | 34 |
| 319 | Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials. Circulation, 2021, 144, 1193-1195. | 1.6 | 34 |
| 320 | Effects of levosimendan on myocardial contractility and oxygen consumption. Journal of Pharmacology and Experimental Therapeutics, 1996, 279, 120-7. | 1.3 | 34 |
| 321 | Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. American Journal of Medicine, 1987, 82, 1119-1126. | 0.6 | 33 |
| 322 | Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1662-1671. | 2.9 | 33 |
| 323 | Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464. | 1.0 | 33 |
| 324 | Are Meta-Analyses a Form of Medical Fake News?. Circulation, 2017, 136, 2097-2099. | 1.6 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure. American Journal of Medicine, 1983, 74, 61-72. | 0.6 | 32 |
| 326 | Do Vasodilators Prolong Life in Heart Failure?. New England Journal of Medicine, 1987, 316, 1471-1473. | 13.9 | 32 |
| 327 | The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41. | 1.2 | 32 |
| 328 | Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from <scp>EMPERORâ€‹</scp>Reduced. European Journal of Heart Failure, 2022, 24, 708-715. | 2.9 | 32 |
| 329 | Hemodynamic evaluation of hydralazine dosage in refractory heart failure. Clinical Pharmacology and Therapeutics, 1980, 27, 337-346. | 2.3 | 31 |
| 330 | Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. Journal of the American College of Cardiology, 1983, 2, 338-344. | 1.2 | 31 |
| 331 | Influence of Renal Function on the Hemodynamic and Clinical Responses to Long-Term Captopril Therapy in Severe Chronic Heart Failure. Annals of Internal Medicine, 1986, 104, 147. | 2.0 | 31 |
| 332 | Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. American Journal of Cardiology, 2002, 90, 969-973. | 0.7 | 31 |
| 333 | Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 399-407. | 1.9 | 31 |
| 334 | Rationale for and design of the <scp>TRUEâ€‹AHF</scp> trial: the effects of ularitide on the shortâ€‹term clinical course and longâ€‹term mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681. | 2.9 | 31 |
| 335 | Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovascular Diabetology, 2018, 17, 9. | 2.7 | 31 |
| 336 | Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil. American Journal of Cardiology, 1982, 50, 886-893. | 0.7 | 30 |
| 337 | Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. International Journal of Cardiology, 1985, 7, 111-120. | 0.8 | 30 |
| 338 | Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: Results of a randomized crossover study. American Heart Journal, 1985, 109, 1293-1299. | 1.2 | 30 |
| 339 | Adverse Hemodynamic and Clinical Effects of Encainide in Severe Chronic Heart Failure. Annals of Internal Medicine, 1989, 110, 505. | 2.0 | 30 |
| 340 | Molecular, Cellular, and Clinical Evidence That Sodiumâ€‹Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure. Journal of the American Heart Association, 2020, 9, e016270. | 1.6 | 30 |
| 341 | How Should Physicians Assess Myocardial Contraction?. JACC: Cardiovascular Imaging, 2020, 13, 873-878. | 2.3 | 30 |
| 342 | Epicardial fat in heart failure with reduced versus preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 835-838. | 2.9 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Concentrationâ€dependent clinical and prognostic importance of highâ€sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <scp>EMPEROR</scp>â€Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538. | 2.9 | 30 |
| 344 | Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509. | 2.9 | 30 |
| 345 | Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal, 2022, 43, 2984-2993. | 1.0 | 30 |
| 346 | Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. Journal of the American College of Cardiology, 1985, 6, 635-645. | 1.2 | 29 |
| 347 | Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. American Journal of Medicine, 2020, 133, e25-e31. | 0.6 | 29 |
| 348 | Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 35-45. | 5.5 | 29 |
| 349 | Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure. American Journal of Cardiology, 1979, 44, 310-317. | 0.7 | 28 |
| 350 | Verapamil therapy for stable and unstable angina pectoris: Calcium channel antagonists in perspective. American Journal of Cardiology, 1982, 50, 881-885. | 0.7 | 28 |
| 351 | Building Castles in the Sky. Circulation, 2018, 138, 751-753. | 1.6 | 28 |
| 352 | Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538. | 2.9 | 28 |
| 353 | Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107647. | 1.2 | 28 |
| 354 | Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the <scp>USA</scp>. European Journal of Heart Failure, 2016, 18, 1211-1219. | 2.9 | 27 |
| 355 | Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation, 1989, 80, IV59-67. | 1.6 | 27 |
| 356 | Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure. American Journal of Cardiology, 1983, 51, 183-188. | 0.7 | 26 |
| 357 | Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. American Journal of Medicine, 1984, 76, 3-13. | 0.6 | 26 |
| 358 | Selecting patients for heart transplantation: which patients are too well for transplant?. Current Opinion in Cardiology, 2002, 17, 137-144. | 0.8 | 26 |
| 359 | Augmentation of glucagonâ€like peptideâ€1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. European Journal of Heart Failure, 2018, 20, 973-977. | 2.9 | 26 |
| 360 | Contrasting hemodynamic responses in severe heart failure: Comparison of captopril and other vasodilator drugs. American Heart Journal, 1982, 104, 1215-1223. | 1.2 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | The Alchemistâ€™s Nightmare. Circulation, 2018, 137, 2068-2073. | 1.6 | 25 |
| 362 | Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901. | 1.6 | 25 |
| 363 | Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Canadian Journal of Cardiology, 2005, 21, 39-43. | 0.8 | 24 |
| 364 | Is It Ethical to Administer Vasodilator Drugs to Patients with Primary Pulmonary Hypertension?. Chest, 1989, 95, 1173-1175. | 0.4 | 23 |
| 365 | Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the assessment of treatment with lisinopril and survival (ATLAS) study. Clinical Therapeutics, 2004, 26, 694-703. | 1.1 | 22 |
| 366 | Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. European Heart Journal, 2005, 26, 2154-2158. | 1.0 | 22 |
| 367 | Is metformin beneficial for heart failure in patients with type 2 diabetes?. Diabetes Research and Clinical Practice, 2018, 136, 168-170. | 1.1 | 22 |
| 368 | Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118. | 1.6 | 22 |
| 369 | Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. American Journal of Cardiology, 1984, 54, 1025-1029. | 0.7 | 21 |
| 370 | Second generation calcium channel blockers in the treatment of chronic heart failure: Are they any better than their predecessors?*. Journal of the American College of Cardiology, 1989, 14, 1339-1342. | 1.2 | 21 |
| 371 | Issues in regulatory guidelines for data monitoring committees. Clinical Trials, 2004, 1, 162-169. | 0.7 | 21 |
| 372 | Unbelievable Folly of Clinical Trials in Heart Failure. Circulation: Heart Failure, 2016, 9, e002837. | 1.6 | 21 |
| 373 | Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPERORâ€Preserved</scp> trial. European Journal of Heart Failure, 2021, 23, 1798-1799. | 2.9 | 21 |
| 374 | Integrating High-Sensitivity Troponin T andÂSacubitril/Valsartan Treatment inÂHFpEF. JACC: Heart Failure, 2021, 9, 627-635. | 1.9 | 21 |
| 375 | Biomarkerâ€driven prognostic models in chronic heart failure with preserved ejection fraction: the <scp>EMPEROR</scp>â€“Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878. | 2.9 | 21 |
| 376 | Empagliflozin Improves Outcomes inÂPatients With HeartÂFailure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18. | 1.2 | 21 |
| 377 | Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: The price we pay for interfering with evolution. Journal of the American College of Cardiology, 1985, 6, 171-173. | 1.2 | 20 |
| 378 | Beta-blockade in the management of chronic heart failure: Another step in the conceptual evolution of a neurohormonal model of the disease. European Heart Journal, 1996, 17, 21-23. | 1.0 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Potentiation of Insulin Signaling Contributes to Heart Failure inÂTypeÂ2ÂDiabetes. JACC Basic To Translational Science, 2018, 3, 415-419. | 1.9 | 20 |
| 380 | The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. European Journal of Heart Failure, 2019, 21, 156-162. | 2.9 | 20 |
| 381 | Totality of evidence in trials of sodiumâ€"glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal, 2020, 41, 3398-3401. | 1.0 | 20 |
| 382 | Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€HF. Journal of the American Heart Association, 2021, 10, e019238. | 1.6 | 20 |
| 383 | Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 1518-1524. | 2.9 | 20 |
| 384 | Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 551-561. | 2.9 | 20 |
| 385 | Prognostic Implications of N-Terminal Proâ€"B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. JACC: Heart Failure, 2022, 10, 512-524. | 1.9 | 20 |
| 386 | II. Protagonist's viewpoint. Journal of the American College of Cardiology, 1988, 12, 562-566. | 1.2 | 19 |
| 387 | Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. American Heart Journal, 2003, 145, 926-932. | 1.2 | 19 |
| 388 | Sacubitrilâ€"Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It?. Annals of Internal Medicine, 2016, 165, 735. | 2.0 | 19 |
| 389 | Heart Failure With a Mid-Range Ejection Fraction. JACC: Heart Failure, 2017, 5, 805-807. | 1.9 | 19 |
| 390 | HFpEF Is the Substrate for Stroke in Obesity and Diabetes Independent ofÂAtrial Fibrillation. JACC: Heart Failure, 2020, 8, 35-42. | 1.9 | 19 |
| 391 | Design of a prospective patientâ€level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398. | 2.9 | 19 |
| 392 | Early changes in estimated glomerular filtration rate postâ€initiation of empagliflozin in <scp>EMPERORâ€Reduced</scp>. European Journal of Heart Failure, 2022, 24, 1829-1839. | 2.9 | 19 |
| 393 | Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs. American Journal of Cardiology, 1981, 48, 375-379. | 0.7 | 18 |
| 394 | Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. JACC: Heart Failure, 2016, 4, 403-408. | 1.9 | 18 |
| 395 | Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors. American Journal of Nephrology, 2020, 51, 289-293. | 1.4 | 18 |
| 396 | Atrial Fibrillation in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346. | 1.9 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders. American Journal of Cardiology, 1986, 57, 853-858. | 0.7 | 17 |
| 398 | Deleterious hemodynamic effects of lidocaine in severe congestive heart failure. American Heart Journal, 1989, 118, 611-612. | 1.2 | 17 |
| 399 | Angiotensin Neprilysin Inhibition for Patients With Heart Failure. JAMA Cardiology, 2016, 1, 971. | 3.0 | 17 |
| 400 | Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care. European Heart Journal, 2020, 41, 2393-2396. | 1.0 | 17 |
| 401 | Mechanisms of nitrate action in patients with severe left ventricular failure: Conceptual problems with the theory of venosequestration. American Heart Journal, 1985, 110, 259-264. | 1.2 | 16 |
| 402 | Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. European Journal of Heart Failure, 1999, 1, 73-79. | 2.9 | 16 |
| 403 | Are Î²-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. American Heart Journal, 2006, 151, 55-61. | 1.2 | 16 |
| 404 | Data sharing in medical research. BMJ: British Medical Journal, 2018, 360, k510. | 2.4 | 16 |
| 405 | Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation, 1990, 82, I77-88. | 1.6 | 16 |
| 406 | Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. American Heart Journal, 2000, 139, S202-S206. | 1.2 | 15 |
| 407 | A device is not a drug. Journal of Cardiac Failure, 2003, 9, 155-157. | 0.7 | 15 |
| 408 | Vasopressor Response to Angiotensin II Infusion in Patients With Chronic Heart Failure Receiving Î²-Blockers. Circulation, 2003, 107, 290-293. | 1.6 | 15 |
| 409 | Lack of Bioequivalence between Different Formulations of Isosorbide??Dinitrate and Hydralazine and??the??Fixed-Dose Combination of??Isosorbide Dinitrate/Hydralazine. Clinical Pharmacokinetics, 2007, 46, 885-895. | 1.6 | 15 |
| 410 | Post hoc analyses of SHIFT and PARADIGMâ€HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: â€œSafety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trialâ€•by Bocchi et al.. ESC Heart Failure, 2018, 5, 1069-1071. | 1.4 | 15 |
| 411 | Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 23-25. | 2.9 | 15 |
| 412 | Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in Psoriasis. American Journal of Medicine, 2020, 133, 267-272. | 0.6 | 15 |
| 413 | Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment. American Journal of Medicine, 2020, 133, 781-782. | 0.6 | 15 |
| 414 | Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958. | 1.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e022069. | 1.6 | 15 |
| 416 | Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 794-803. | 2.9 | 15 |
| 417 | The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1989, 7, S33-6. | 0.1 | 15 |
| 418 | Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation, 1988, 77, I64-73. | 1.6 | 15 |
| 419 | Prognostic value of echocardiographic evaluation of septal function in acute anteroseptal myocardial infarction. American Heart Journal, 1979, 97, 726-732. | 1.2 | 14 |
| 420 | Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 1993, 22, 963-967. | 1.2 | 14 |
| 421 | Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications. European Journal of Heart Failure, 2018, 20, 1100-1105. | 2.9 | 14 |
| 422 | Acute Heart Failure Is an Event RatherÂThan a Disease. JACC: Heart Failure, 2018, 6, 73-75. | 1.9 | 14 |
| 423 | Will longâ€acting glucagonâ€like peptideâ€1 analogues recapitulate our agonizing experience with cyclic AMPâ€dependent positive inotropic agents in heart failure?. European Journal of Heart Failure, 2018, 20, 627-629. | 2.9 | 14 |
| 424 | Neurohormonal and Transcatheter Repair Strategies for Proportionate and Disproportionate Functional Mitral Regurgitation in Heart Failure. JACC: Heart Failure, 2019, 7, 518-521. | 1.9 | 14 |
| 425 | Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379. | 2.9 | 14 |
| 426 | <scp>Angiotensinâ€“neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598. | 2.9 | 14 |
| 427 | Outcomes with empagliflozin in heart failure with preserved ejection fraction using <scp>DELIVER</scp>â€like endpoint definitions. European Journal of Heart Failure, 2022, 24, 1400-1405. | 2.9 | 14 |
| 428 | Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. American Heart Journal, 1998, 135, 389-397. | 1.2 | 13 |
| 429 | Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. International Journal of Cardiology, 2005, 100, 143-149. | 0.8 | 13 |
| 430 | Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study. Chest, 2014, 146, 860A. | 0.4 | 13 |
| 431 | Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052. | 1.6 | 13 |
| 432 | Distinguishing Proportionate and Disproportionate Subtypes in FunctionalÂMitral Regurgitation and LeftÂVentricular Systolic Dysfunction. JACC: Cardiovascular Imaging, 2021, 14, 726-729. | 2.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | Selection of Vasodilator Drugs for Patients with Severe Chronic Heart Failure. Drugs, 1982, 24, 64-74. | 4.9 | 12 |
| 434 | The clinical significance of nitrate tolerance in patients with chronic heart failure. European Heart Journal, 1989, 10, 20-25. | 1.0 | 12 |
| 435 | Is the Way to Someoneâ€™s Heart Through Their Stomach?. Circulation: Heart Failure, 2017, 10, . | 1.6 | 12 |
| 436 | Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial. European Journal of Heart Failure, 2018, 20, 49-51. | 2.9 | 12 |
| 437 | Why Are Physicians So Confused about Acute Heart Failure?. New England Journal of Medicine, 2019, 381, 776-777. | 13.9 | 12 |
| 438 | Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure. European Journal of Heart Failure, 2019, 21, 823-826. | 2.9 | 12 |
| 439 | Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784. | 2.9 | 12 |
| 440 | Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results?. Annals of Internal Medicine, 1988, 109, 3. | 2.0 | 11 |
| 441 | The effect of treatment on survival in congestive heart failure. Clinical Cardiology, 1992, 15, 323-329. | 0.7 | 11 |
| 442 | The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines. Journal of Cardiac Failure, 2016, 22, 726-730. | 0.7 | 11 |
| 443 | Heart Failureâ€™s Dark Secret. Circulation, 2016, 134, 629-631. | 1.6 | 11 |
| 444 | Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Medicine, 2019, 132, 1311-1319. | 0.6 | 11 |
| 445 | Effectiveness of Medical Therapy for Functional MitralÂRegurgitation in HeartÂFailure With ReducedÂEjection Fraction. Journal of the American College of Cardiology, 2020, 76, 883-884. | 1.2 | 11 |
| 446 | Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal, 2021, 42, 4887-4890. | 1.0 | 11 |
| 447 | Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356. | 2.9 | 11 |
| 448 | Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgraduate Medical Journal, 1986, 62 Suppl 1, 179-82. | 0.9 | 11 |
| 449 | Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153. | 2.9 | 11 |
| 450 | Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint. American Journal of Cardiology, 1990, 66, 458-461. | 0.7 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Management of patients with heart failure and angina: Do coexistent diseases alter the response to cardiovascular drugs?. Journal of the American College of Cardiology, 1991, 17, 740-742. | 1.2 | 10 |
| 452 | Calcium antagonists for congestive heart failure: Evolving concepts in bridge building. Cardiovascular Drugs and Therapy, 1993, 7, 95-96. | 1.3 | 10 |
| 453 | The Imminent Demise of Cardiovascular Drug Development. JAMA Cardiology, 2017, 2, 1293. | 3.0 | 10 |
| 454 | Role of the sodiumâ€hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 800-811. | 2.2 | 10 |
| 455 | Side effects and treatment initiation barriers of sodiumâ€“glucose cotransporter 2 inhibitors in heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1625-1632. | 2.9 | 10 |
| 456 | Double Vision. JACC: Heart Failure, 2017, 5, 232-235. | 1.9 | 9 |
| 457 | Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007430. | 2.1 | 9 |
| 458 | Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGMâ€HF. ESC Heart Failure, 2020, 7, 3355-3364. | 1.4 | 9 |
| 459 | Potential Role of Atrial Myopathy in the Pathogenesis of Stroke in Rheumatoid Arthritis and Psoriasis: A Conceptual Framework and Implications for Prophylaxis. Journal of the American Heart Association, 2020, 9, e014764. | 1.6 | 9 |
| 460 | Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?. European Journal of Heart Failure, 2020, 22, 173-176. | 2.9 | 9 |
| 461 | Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2020, 133, 1187-1194. | 0.6 | 9 |
| 462 | Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484. | 2.9 | 9 |
| 463 | Ophthalmology's botanical heritage. Survey of Ophthalmology, 1992, 36, 357-365. | 1.7 | 8 |
| 464 | Simultaneous Modeling of the Pharmacokinetic and Pharmacodynamic Properties of Enalkiren (Abbott-64662, A Renin Inhibitor). II. Journal of Cardiovascular Pharmacology, 1993, 21, 834-840. | 0.8 | 8 |
| 465 | Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. JAMA Cardiology, 2018, 3, 883. | 3.0 | 8 |
| 466 | Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400. | 1.0 | 8 |
| 467 | Central hemodynamic effects of dipyridamole in severe heart failure: Comparison with hydralazine. Clinical Pharmacology and Therapeutics, 1982, 32, 54-61. | 2.3 | 7 |
| 468 | Diastolic function as a target of therapeutic interventions in chronic heart failure. European Heart Journal, 1990, 11, 35-40. | 1.0 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: Experience from trials of flosequinan. American Heart Journal, 1996, 132, 130-136. | 1.2 | 7 |
| 470 | The Future Treatment of Heart Failure?. European Heart Journal, 2018, 39, 5-7. | 1.0 | 7 |
| 471 | Do Most Obese People with Exercise Intolerance and a Normal Ejection Fraction Have Treatable Heart Failure?. American Journal of Medicine, 2018, 131, 863-864. | 0.6 | 7 |
| 472 | Why is the use of digitalis withering? Another reason that we need medical heart failure specialists. European Journal of Heart Failure, 2018, 20, 851-852. | 2.9 | 7 |
| 473 | Neurohormonal Antagonists AreÂPreferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in HeartÂFailure. JACC: Heart Failure, 2019, 7, 902-906. | 1.9 | 7 |
| 474 | Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications. Heart, 2021, 107, 528-534. | 1.2 | 7 |
| 475 | Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure. Circulation: Heart Failure, 2021, 14, e008537. | 1.6 | 7 |
| 476 | Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. Journal of Cardiac Failure, 2015, 21, S9-S10. | 0.7 | 6 |
| 477 | How have millions of people with heart failure benefited from our research over the last 10â€“15 years? The sounds of dead silence. European Journal of Heart Failure, 2017, 19, 1353-1354. | 2.9 | 6 |
| 478 | Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development. Journal of Cardiac Failure, 2017, 23, 697-699. | 0.7 | 6 |
| 479 | Have we really demonstrated the cardiovascular safety of antiâ€hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1089-1095. | 2.2 | 6 |
| 480 | Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. International Journal of Cardiology, 2018, 261, 130-133. | 0.8 | 6 |
| 481 | Future largeâ€scale clinical trials in cardiovascular medicine: challenges and uncertainties. European Journal of Heart Failure, 2018, 20, 1645-1648. | 2.9 | 6 |
| 482 | Questioning the obvious: does dyspnoea really matter in heart failure?. European Heart Journal, 2018, 39, 2822-2824. | 1.0 | 6 |
| 483 | Critical role of the epicardium in mediating cardiac inflammation and fibrosis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1765-1768. | 2.2 | 6 |
| 484 | Ten lessons from the <scp>EMPERORâ€Reduced</scp> trial. European Journal of Heart Failure, 2020, 22, 1991-1993. | 2.9 | 6 |
| 485 | Comparative Immediate Hemodynamic and Hormonal Effects of Amrinone and Captopril in Patients with Severe Chronic Heart Failure. American Journal of the Medical Sciences, 1986, 291, 8-15. | 0.4 | 6 |
| 486 | Natriuretic peptideâ€based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 672-677. | 2.9 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Is There a Drug of Choice for Vasodilator Therapy in Patients with Refractory Heart Failure?. Chest, 1980, 77, 7-9. | 0.4 | 5 |
| 488 | Foreword. Journal of the American College of Cardiology, 1988, 12, 262-264. | 1.2 | 5 |
| 489 | The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure, 2012, 18, 883. | 0.7 | 5 |
| 490 | Who Should Deliver Medical Therapy for Patients With Chronic Heart Failure?. Circulation: Heart Failure, 2017, 10, . | 1.6 | 5 |
| 491 | Role of Payers in the Development of Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2017, 70, 2822-2830. | 1.2 | 5 |
| 492 | Does a Target Dose or a Target Heart Rate Matter to Outcomes When Prescribing Î²-Blockers to Patients With Chronic Heart Failure?. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004605. | 0.9 | 5 |
| 493 | Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?. Journal of Cardiac Failure, 2018, 24, 109-111. | 0.7 | 5 |
| 494 | Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. American Journal of Medicine, 2018, 131, 461-463. | 0.6 | 5 |
| 495 | Methodological and Clinical Heterogeneity and Extraction Errors in Metaâ€Analyses of Catheter Ablation for Atrial Fibrillation in Heart Failure. Journal of the American Heart Association, 2019, 8, e013779. | 1.6 | 5 |
| 496 | Heightened risk of intensive rate control in patients with atrial fibrillation who are obese or have type 2 diabetes: A critical review and reâ€evaluation. Journal of Cardiovascular Electrophysiology, 2019, 30, 3020-3024. | 0.8 | 5 |
| 497 | What Have We Learned From Randomized Controlled Trials of Catheter Ablation for Atrial Fibrillation in Patients With Chronic Heart Failure?. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007222. | 2.1 | 5 |
| 498 | Effect of Empagliflozin on Cardiovascular and Kidney Outcomes in Patients with Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial. , 2021, 16, . | | 5 |
| 499 | Influence of Study Discontinuation during the Runâ€in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGONâ€HF Trial. European Journal of Heart Failure, 2021, , . | 2.9 | 5 |
| 500 | The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. European Journal of Heart Failure, 2021, 23, 1872-1874. | 2.9 | 5 |
| 501 | Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes. Journal of Cardiac Failure, 2022, 28, 682-683. | 0.7 | 5 |
| 502 | Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective. Circulation, 1990, 82, I1-6. | 1.6 | 5 |
| 503 | The Complex Phenotypic Expressions of Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2021, 78, 2422-2424. | 1.2 | 5 |
| 504 | Lymphocyte G proteins reflect response to treatment in congestive heart failure. American Heart Journal, 1995, 129, 98-106. | 1.2 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. Journal of the American College of Cardiology, 2017, 69, 919. | 1.2 | 4 |
| 506 | Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. Diabetes, Obesity and Metabolism, 2018, 20, 1766-1769. | 2.2 | 4 |
| 507 | Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. Diabetic Medicine, 2018, 35, 707-713. | 1.2 | 4 |
| 508 | The CABANA Trial: an honourable view. European Heart Journal, 2018, 39, 2770-2770. | 1.0 | 4 |
| 509 | Nonarrhythmic Sudden Cardiac Death in Chronic Heart Failureâ€"A Preventable Event?. JAMA Cardiology, 2019, 4, 721. | 3.0 | 4 |
| 510 | When Cardiovascular Trials Collide. European Heart Journal, 2019, 40, 501-504. | 1.0 | 4 |
| 511 | Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists. Journal of Cardiovascular Pharmacology, 1989, 14 Suppl 5, S38-43. | 0.8 | 4 |
| 512 | Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure. Survey of Anesthesiology, 1988, 32, 86. | 0.1 | 3 |
| 513 | Controlled-Release Carvedilol: A Concluding Perspective. American Journal of Cardiology, 2006, 98, 67-69. | 0.7 | 3 |
| 514 | The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. American Journal of Cardiology, 2008, 102, 1046-1055. | 0.7 | 3 |
| 515 | Tetralogy of Fallow. JACC: Heart Failure, 2017, 5, 408-410. | 1.9 | 3 |
| 516 | Absence of an Ideal Observer II. Circulation, 2017, 136, 2400-2402. | 1.6 | 3 |
| 517 | Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials. American Journal of Medicine, 2018, 131, e287-e289. | 0.6 | 3 |
| 518 | Early Worsening of Renal Function After Treatment with Antihyperglycemic Drugs: A Consistent Finding in Large-Scale Trials. American Journal of Medicine, 2018, 131, 337-338. | 0.6 | 3 |
| 519 | The Parable of SchrÃ¶dingerâ€™s Cat and the Illusion of Statistical Significance in Clinical Trials. Circulation, 2019, 140, 799-800. | 1.6 | 3 |
| 520 | A Compelling Case for Less Aggressive Arrhythmia Management in Patients With Chronic Heart Failure and Long-Standing Atrial Fibrillation. Journal of Cardiac Failure, 2020, 26, 85-92. | 0.7 | 3 |
| 521 | Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. American Heart Journal, 2021, 237, 45-53. | 1.2 | 3 |
| 522 | A novel approach to the development of positive inotropic agents for chronic heart failure. Journal of Cardiovascular Pharmacology, 1995, 26 Suppl 1, S52-6. | 0.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | Does digitalis work in chronic heart failure? The end of a 200-year-old controversy. Cardiovascular Drugs and Therapy, 1989, 2, 743-746. | 1.3 | 2 |
| 524 | Cardiac failure: editorial overview. Current Opinion in Cardiology, 1989, 4, 339-341. | 0.8 | 2 |
| 525 | How do vasodilators improve cardiac performance in chronic heart failure? Insights gained from two-dimensional color flow Doppler echocardiography. Journal of the American College of Cardiology, 1990, 15, A150. | 1.2 | 2 |
| 526 | 965-51 Daily Coronary Microembolization in Awake Dogs Leads to Heart Failure. Journal of the American College of Cardiology, 1995, 25, 222A-223A. | 1.2 | 2 |
| 527 | Key issues in trial design for ventricular assist devices: a position statement of the heart failure society of America. Journal of Cardiac Failure, 2004, 10, 91-100. | 0.7 | 2 |
| 528 | Data sharing: lessons from Copernicus and Kepler. BMJ, The, 2016, 354, i4911. | 3.0 | 2 |
| 529 | The Absence of an Ideal Observer. Circulation, 2017, 136, 1085-1086. | 1.6 | 2 |
| 530 | Is Any Patient with Chronic Heart Failure Receiving the Right Dose of the Right Beta-Blocker in Primary Care?. American Journal of Medicine, 2019, 132, e761-e762. | 0.6 | 2 |
| 531 | Is Long-Standing Atrial Fibrillation a Biomarker of or Contributor to the Symptoms or Progression of Chronic Heart Failure?. American Journal of Medicine, 2020, 133, 17-18. | 0.6 | 2 |
| 532 | Concerns about the use of metformin as a first-line agent to slow the progression of chronic kidney disease in diabetes. Diabetes Research and Clinical Practice, 2020, 160, 108024. | 1.1 | 2 |
| 533 | What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure. European Journal of Heart Failure, 2021, 23, 797-799. | 2.9 | 2 |
| 534 | Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy. Chest, 1985, 88, 265S-268. | 0.4 | 2 |
| 535 | Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure. Nature Reviews Cardiology, 2022, 19, 499-500. | 6.1 | 2 |
| 536 | Panel discussion I: Evaluation and management of chronic heart failure. Journal of the American College of Cardiology, 1993, 22, A201-A203. | 1.2 | 1 |
| 537 | Nitric oxide (NO) is the mediator responsible for physical training-normalized vasodilation of epicardial coronary artery during development of heart failure (HF). Journal of the American College of Cardiology, 1996, 27, 322. | 1.2 | 1 |
| 538 | Circadian rhythm and sudden death in heart failure: Results from praise. Journal of the American College of Cardiology, 1996, 27, 280. | 1.2 | 1 |
| 539 | Should recommendations for clinical use be restricted to patients who were enrolled in a pivotal clinical trial?. European Journal of Heart Failure, 2017, 19, 779-781. | 2.9 | 1 |
| 540 | CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: INSIGHTS FROM PARADIGM-HF. Journal of the American College of Cardiology, 2017, 69, 734. | 1.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartanâ€"Reply. JAMA Cardiology, 2017, 2, 819. | 3.0 | 1 |
| 542 | Risks of Intensive Treatment of Long-Standing Atrial Fibrillation in Patients With Chronic Heart Failure With a Reduced or Preserved Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005747. | 0.9 | 1 |
| 543 | Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the reninâ€"angiotensin system in chronic heart failure? The culmination of a 20-year journey. European Heart Journal, 2019, 40, 3353-3355. | 1.0 | 1 |
| 544 | Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atrial myopathy of patients with atrial fibrillation? A provocative hypothesis. Europace, 2020, 22, 681-683. | 0.7 | 1 |
| 545 | Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure. , 2021, 16, . | | 1 |
| 546 | Link Between Synovial and Myocardial Inflammation: Conceptual Framework to Explain the Pathogenesis of Heart Failure with Preserved Ejection Fraction in Patients with Systemic Rheumatic Diseases. Cardiac Failure Review, 0, 6, . | 1.2 | 1 |
| 547 | Modulation of functional capacity and survival in congestive heart failure. Effects of activation of the sympathetic nervous system. Postgraduate Medicine, 1988, Spec No, 96-103. | 0.9 | 1 |
| 548 | Is the erythrocyte sedimentation rate a useful marker of the response to therapy in heart failure? A re-evaluation after 50 years. Journal of the American College of Cardiology, 1991, 17, A89. | 1.2 | 0 |
| 549 | Discussion II. Journal of the American College of Cardiology, 1993, 22, A41-A42. | 1.2 | 0 |
| 550 | Discussion VII. Journal of the American College of Cardiology, 1993, 22, A162-A164. | 1.2 | 0 |
| 551 | Discussion IX. Journal of the American College of Cardiology, 1993, 22, A192-A193. | 1.2 | 0 |
| 552 | Panel discussion II: Directions for future research. Journal of the American College of Cardiology, 1993, 22, A204-A205. | 1.2 | 0 |
| 553 | 901-74 Delayed and Incomplete Reversal of Impaired Metabolic Vasodilation in Patients with Heart Failure During Long-term Circulatory Support with a Left Ventricular Assist Device. Journal of the American College of Cardiology, 1995, 25, 22A-23A. | 1.2 | 0 |
| 554 | 757-5 Hemodynamic Effects of Synthetic Human Brain Natriuretic Peptide Infusion in Patients with Severe Congestive Heart Failure: A Placebo-controlled, Crossover Trial. Journal of the American College of Cardiology, 1995, 25, 235A. | 1.2 | 0 |
| 555 | Prediction of maximal oxygen consumption by six minute walk testing in patients with congestive heart failure. Journal of the American College of Cardiology, 1996, 27, 216-217. | 1.2 | 0 |
| 556 | Physician global assessment of heart failure patients: comparison with patient global assessment and quality of life scores in the ATTACH trial. Journal of Cardiac Failure, 2004, 10, S80. | 0.7 | 0 |
| 557 | Effect of digoxin withdrawal in patients with chronic heart failure receiving carvedilol. Journal of Cardiac Failure, 2004, 10, S87. | 0.7 | 0 |
| 558 | Controlled-Release Carvedilol in Heart Failure and Post-MI LVD: Pharmacokinetics, Pharmacodynamics and Safety. Journal of Cardiac Failure, 2006, 12, S71-S72. | 0.7 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536. | 1.2 | 0 |
| 560 | Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization. Journal of Cardiac Failure, 2016, 22, S24. | 0.7 | 0 |
| 561 | Association between Baseline, and Changes in, Health-Related Quality of Life and Death and HF Hospitalization in PARADIGM-HF. Journal of Cardiac Failure, 2016, 22, S92. | 0.7 | 0 |
| 562 | Response by Packer to Letter Regarding Article, â€œDevelopment and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspectiveâ€• Circulation, 2017, 135, e892-e893. | 1.6 | 0 |
| 563 | Sacubitrilâ€“Valsartan in Heart Failure. Annals of Internal Medicine, 2017, 166, 681. | 2.0 | 0 |
| 564 | Response by Packer to Letter Regarding Article, â€œActivation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failureâ€• Circulation, 2018, 137, 1981-1982. | 1.6 | 0 |
| 565 | Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. Journal of Diabetes and Its Complications, 2018, 32, 616-617. | 1.2 | 0 |
| 566 | Response by Dr Packer to the Letter of Dr Blankfield. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 99-100. | 1.0 | 0 |
| 567 | The Reply. American Journal of Medicine, 2018, 131, e427. | 0.6 | 0 |
| 568 | Risk of heart failure in diabetic patients receiving sulfonylureas: reply. European Journal of Heart Failure, 2018, 20, 1372-1372. | 2.9 | 0 |
| 569 | P2630Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction. European Heart Journal, 2019, 40, . | 1.0 | 0 |
| 570 | Defining Secondary Mitral Regurgitation: Evidence that the 2017 Updated Guidelines Got it Right. Structural Heart, 2019, 3, 284-287. | 0.2 | 0 |
| 571 | Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation. European Journal of Heart Failure, 2019, 21, 398-401. | 2.9 | 0 |
| 572 | Beth Levine In Memoriam. European Heart Journal, 2020, 41, 2617-2617. | 1.0 | 0 |
| 573 | Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030. | 0.7 | 0 |
| 574 | Abstract 17955: Reduction in 30-day Rehospitalization After Discharge From a Heart Failure Admission in Patients Receiving LCZ696 versus Enalapril: PARADIGM-HF. Circulation, 2015, 132, . | 1.6 | 0 |
| 575 | Due process. Western Journal of Medicine, 1990, 153, 91-2. | 0.3 | 0 |
| 576 | Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. European Heart Journal, 1998, 19 Suppl B, B40-6. | 1.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 577 | HF-567-01 THE BENEFIT OF AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN HEART FAILURE PATIENTS TREATED WITH EMPAGLIFLOZIN: AN ANALYSIS FROM THE EMPEROR-REDUCED TRIAL. Heart Rhythm, 2022, 19, S72-S73. | 0.3 | 0 |